EMA/291493/2024

European Medicines Agency decision

P/0227/2024

of 19 July 2024

on the acceptance of a modification of an agreed paediatric investigation plan for mexiletine (hydrochloride) (Namuscla), (EMEA-002012-PIP01-16-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0227/2024

of 19 July 2024

on the acceptance of a modification of an agreed paediatric investigation plan for mexiletine (hydrochloride) (Namuscla), (EMEA-002012-PIP01-16-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0155/2017 issued on 2 June 2017, the decision P/0210/2018 issued on 17 July 2018, the decision P/0425/2019 issued on 4 December 2019, the decision P/0365/2021 issued on 8 September 2021, and the decision P/0300/2023 issued on 11 August 2023,

Having regard to the application submitted by Lupin Europe GmbH on 23 February 2024 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 31 May 2024, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Article 1

Changes to the agreed paediatric investigation plan for mexiletine (hydrochloride) (Namuscla), capsule, hard, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Lupin Europe GmbH, Hanauer Landstrasse 139-143, 60314 – Frankfurt, Germany.

EMA/PDCO/90756/2024
Amsterdam, 31 May 2024

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-002012-PIP01-16-M05

Scope of the application

Active substance(s):

Mexiletine (hydrochloride)

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of myotonic disorders

Pharmaceutical form(s):

Capsule, hard

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Lupin Europe GmbH

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Lupin Europe GmbH submitted to the European Medicines Agency on 23 February 2024 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0155/2017 issued on 2 June 2017, the decision P/0210/2018 issued on 17 July 2018, the decision P/0425/2019 issued on 4 December 2019, the decision P/0365/2021 issued on 8 September 2021, and the decision P/0300/2023 issued on 11 August 2023.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 2 April 2024.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
    - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.
2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition

Treatment of myotonic disorders

2.1.1. Indication(s) targeted by the PIP

Symptomatic treatment of myotonic disorders

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Capsule, hard

2.1.4. Measures

Area	Description
Quality-related studies	**Study 1** Development of age-appropriate solid formulation (capsule, not containing erythrosine as colorant) in lower strengths appropriate to the paediatric population **Study 2** *This study was deleted as a result of procedure EMEA-002012-PIP01-16-M03.*
Non-clinical studies	**Study 3** 11-week toxicity study in juvenile rats with a 4-week recovery period
Clinical studies	**Study 4** Open-label, non-comparative study to evaluate the PK, safety and efficacy of mexiletine in children and adolescents 6 to less than 18 years of age with clinical symptoms or signs of myotonic disorders (MEX-NM-301, EudraCT number 2019-003757-28) **Study 5** Prospective, long-term observational study (registry) of paediatric myotonic disorder patients from birth to less than 6 years of age who are treated with mexiletine (MEX-NM-401)

	Study 6 *This study was deleted as a result of procedure EMEA-002012-PIP01-16-M01.* **Study 7** Open-label follow-up study evaluating the long-term safety and efficacy of mexiletine in children with myotonic disorders who have completed the initial paediatric studies (MEX-NM-303, EudraCT number 2019-003758-97)
Extrapolation, modelling and simulation studies	**Study 8** PK modelling study to support dosing recommendations in children
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2027
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of myotonic disorders

Authorised indication(s):

- Symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders
  - Invented name(s): Namuscla
  - Authorised pharmaceutical form(s): Capsule, hard
  - Authorised route(s) of administration: Oral use
  - Authorised via centralised procedure